This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, H. Articles by Bai, W. Search for Related Content PubMed PubMed Citation Articles by Lee, H. Articles by Bai, W.

MEKK1 Activation of Human Estrogen Receptor and Stimulation of the Agonistic Activity of 4-Hydroxytamoxifen in Endometrial and Ovarian Cancer Cells

Department of Pathology (H.L., F.J., Q.W., S.V.N., W.B.) University of South Florida College of Medicine and H. Lee Moffitt Cancer Center Tampa, Florida 33612-4799
Department of Immunology (J.Y., B.S.) M. D. Anderson Cancer Center Houston, Texas 77030

Estrogens are mitogens that stimulate the growth of both normal and transformed epithelial cells of the female reproductive system. The effect of estrogens is mediated through the estrogen receptors, which are ligand-regulated transcription factors. Tamoxifen, a selective estrogen receptor modulator, functions as an estrogen receptor antagonist in breast but an agonist in uterus. In the current study, we show that coexpression of a constitutively active MEKK1, but not RAF or MEKK2, significantly increases the transcriptional activity of the receptor in endometrial and ovarian cancer cells. The expression of wild-type MEKK1 and an active Rac1, which functions upstream of MEKK1, also increased the activity of the receptor while coexpression of dominant negative MEKK1 blocked the Rac1 induction, indicating that endogenous MEKK1 is capable of activating the receptor. Additional experiments demonstrated that the MEKK1-induced activation was mediated through both Jun N-terminal kinases and p38/Hog1 and was independent of the known phosphorylation sites on the receptor. p38, but not Jun N-terminal kinases, efficiently phosphorylated the receptor in immunocomplex kinase assays, suggesting a differential involvement of the two kinases in the receptor activation. More importantly, the expression of the constitutively active MEKK1 increased the agonistic activity of 4-hydroxytamoxifen to a level comparable to that of 17ß-estradiol and fully blocked its antagonistic activity. These findings suggest that the uterine-specific agonistic activity of the tamoxifen compound may be determined by the status of kinases acting downstream of MEKK1.

This article has been cited by other articles:

				D. Mokhtari, J. W. Myers, and N. Welsh The MAPK Kinase Kinase-1 Is Essential for Stress-Induced Pancreatic Islet Cell Death Endocrinology, June 1, 2008; 149(6): 3046 - 3053. [Abstract] [Full Text] [PDF]

				J. Bao, C. Cao, X. Zhang, F. Jiang, S. V. Nicosia, and W. Bai Suppression of {beta}-Amyloid Precursor Protein Signaling into the Nucleus by Estrogens Mediated through Complex Formation between the Estrogen Receptor and Fe65 Mol. Cell. Biol., February 15, 2007; 27(4): 1321 - 1333. [Abstract] [Full Text] [PDF]

				Q.-P. Li, X. Qi, R. Pramanik, N. M. Pohl, M. Loesch, and G. Chen Stress-induced c-Jun-dependent Vitamin D Receptor (VDR) Activation Dissects the Non-classical VDR Pathway from the Classical VDR Activity J. Biol. Chem., January 19, 2007; 282(3): 1544 - 1551. [Abstract] [Full Text] [PDF]

				B. Liu, J.-f. Wu, Y.-y. Zhan, H.-z. Chen, X.-y. Zhang, and Q. Wu Regulation of the Orphan Receptor TR3 Nuclear Functions by c-Jun N Terminal Kinase Phosphorylation Endocrinology, January 1, 2007; 148(1): 34 - 44. [Abstract] [Full Text] [PDF]

				T M Sadler, M Gavriil, T Annable, P Frost, L M Greenberger, and Y Zhang Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer, September 1, 2006; 13(3): 863 - 873. [Abstract] [Full Text] [PDF]

				D. V. Henley and K. S. Korach Endocrine-Disrupting Chemicals Use Distinct Mechanisms of Action to Modulate Endocrine System Function Endocrinology, June 1, 2006; 147(6): s25 - s32. [Abstract] [Full Text] [PDF]

				D. E. Frigo, A. Basu, E. N. Nierth-Simpson, C. B. Weldon, C. M. Dugan, S. Elliott, B. M. Collins-Burow, V. A. Salvo, Y. Zhu, L. I. Melnik, et al. p38 Mitogen-Activated Protein Kinase Stimulates Estrogen-Mediated Transcription and Proliferation through the Phosphorylation and Potentiation of the p160 Coactivator Glucocorticoid Receptor-Interacting Protein 1 Mol. Endocrinol., May 1, 2006; 20(5): 971 - 983. [Abstract] [Full Text] [PDF]

				A. Vivacqua, D. Bonofiglio, A. G. Recchia, A. M. Musti, D. Picard, S. Ando, and M. Maggiolini The G Protein-Coupled Receptor GPR30 Mediates the Proliferative Effects Induced by 17{beta}-Estradiol and Hydroxytamoxifen in Endometrial Cancer Cells Mol. Endocrinol., March 1, 2006; 20(3): 631 - 646. [Abstract] [Full Text] [PDF]

				X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy J. Clin. Oncol., October 20, 2005; 23(30): 7721 - 7735. [Abstract] [Full Text] [PDF]

				M. C. Gutierrez, S. Detre, S. Johnston, S. K. Mohsin, J. Shou, D. C. Allred, R. Schiff, C. K. Osborne, and M. Dowsett Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase J. Clin. Oncol., April 10, 2005; 23(11): 2469 - 2476. [Abstract] [Full Text] [PDF]

				Y. M. Shah and B. G. Rowan The Src Kinase Pathway Promotes Tamoxifen Agonist Action in Ishikawa Endometrial Cells through Phosphorylation-Dependent Stabilization of Estrogen Receptor {alpha} Promoter Interaction and Elevated Steroid Receptor Coactivator 1 Activity Mol. Endocrinol., March 1, 2005; 19(3): 732 - 748. [Abstract] [Full Text] [PDF]

				M. S. Jansen, S. C. Nagel, P. J. Miranda, E. K. Lobenhofer, C. A. Afshari, and D. P. McDonnell Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition PNAS, May 4, 2004; 101(18): 7199 - 7204. [Abstract] [Full Text] [PDF]

				T. Watanabe, H. Jono, J. Han, D. J. Lim, and J.-D. Li Synergistic activation of NF-{kappa}B by nontypeable Haemophilus influenzae and tumor necrosis factor {alpha} PNAS, March 9, 2004; 101(10): 3563 - 3568. [Abstract] [Full Text] [PDF]

				H. Leong, J. E. Riby, G. L. Firestone, and L. F. Bjeldanes Potent Ligand-Independent Estrogen Receptor Activation by 3,3'-Diindolylmethane Is Mediated by Cross Talk between the Protein Kinase A and Mitogen-Activated Protein Kinase Signaling Pathways Mol. Endocrinol., February 1, 2004; 18(2): 291 - 302. [Abstract] [Full Text] [PDF]

				S. K. Kolluri, N. Bruey-Sedano, X. Cao, B. Lin, F. Lin, Y.-H. Han, M. I. Dawson, and X.-k. Zhang Mitogenic Effect of Orphan Receptor TR3 and Its Regulation by MEKK1 in Lung Cancer Cells Mol. Cell. Biol., December 1, 2003; 23(23): 8651 - 8667. [Abstract] [Full Text] [PDF]

				A. Jones Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why? Ann. Onc., December 1, 2003; 14(12): 1697 - 1704. [Abstract] [Full Text] [PDF]

				F. Jiang, P. Li, A. J. Fornace Jr., S. V. Nicosia, and W. Bai G2/M Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through the Induction of GADD45 via an Exonic Enhancer J. Biol. Chem., November 28, 2003; 278(48): 48030 - 48040. [Abstract] [Full Text] [PDF]

				P. Li, H. Lee, S. Guo, T. G. Unterman, G. Jenster, and W. Bai AKT-Independent Protection of Prostate Cancer Cells from Apoptosis Mediated through Complex Formation between the Androgen Receptor and FKHR Mol. Cell. Biol., January 1, 2003; 23(1): 104 - 118. [Abstract] [Full Text]

				R. Schiff, S. Massarweh, J. Shou, and C. K. Osborne Breast Cancer Endocrine Resistance: How Growth Factor Signaling and Estrogen Receptor Coregulators Modulate Response Clin. Cancer Res., January 1, 2003; 9(1): 447S - 454S. [Abstract] [Full Text] [PDF]

				H. Lee and W. Bai Regulation of Estrogen Receptor Nuclear Export by Ligand-Induced and p38-Mediated Receptor Phosphorylation Mol. Cell. Biol., August 15, 2002; 22(16): 5835 - 5845. [Abstract] [Full Text] [PDF]

				P. H. Driggers, J. H. Segars, and D. M. Rubino The Proto-oncoprotein Brx Activates Estrogen Receptor beta by a p38 Mitogen-activated Protein Kinase Pathway J. Biol. Chem., December 7, 2001; 276(50): 46792 - 46797. [Abstract] [Full Text] [PDF]

				M. J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert-Cussac, F. Janicke, W. R. Miller, D. B. Evans, M. Dugan, C. Brady, et al. Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1- and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial J. Clin. Oncol., September 15, 2001; 19(18): 3808 - 3816. [Abstract] [Full Text] [PDF]

				T. Shen, K. B. Horwitz, and C. A. Lange Transcriptional Hyperactivity of Human Progesterone Receptors Is Coupled to Their Ligand-Dependent Down-Regulation by Mitogen-Activated Protein Kinase-Dependent Phosphorylation of Serine 294 Mol. Cell. Biol., September 15, 2001; 21(18): 6122 - 6131. [Abstract] [Full Text] [PDF]

				M. Sun, J. E. Paciga, R. I. Feldman, Z.-q. Yuan, D. Coppola, Y. Y. Lu, S. A. Shelley, S. V. Nicosia, and J. Q. Cheng Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, Activated in Breast Cancer, Regulates and Is Induced by Estrogen Receptor {alpha} (ER{alpha}) via Interaction between ER{alpha} and PI3K Cancer Res., August 1, 2001; 61(16): 5985 - 5991. [Abstract] [Full Text] [PDF]

				P. Li, S. V. Nicosia, and W. Bai Antagonism between PTEN/MMAC1/TEP-1 and Androgen Receptor in Growth and Apoptosis of Prostatic Cancer Cells J. Biol. Chem., June 1, 2001; 276(23): 20444 - 20450. [Abstract] [Full Text] [PDF]